Direct thrombin inhibitors: Novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation

Postgraduate Medical Journal

Volumn 81, Issue 956, 2005, Pages 370-375

  Katira, R ^a   Chauhan, A ^a   More, R S ^a  

^a BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; LIVER DISEASE; META ANALYSIS; PROPHYLAXIS; REVIEW; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE III; HUMANS; LIVER DISEASES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; THROMBIN; THROMBOEMBOLISM; WARFARIN;

EID: 20644434927     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.024521     Document Type: Review

References (70)

1. Prystowslty EN, Benson W Jr, Fuster V, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996;93:1262-77.
2. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-73.
3. Braunwald E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
4. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA 1994;271:840-4.
5. Kannel WB, Abbot RD, Savage DD, et al. Epidemiological features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-22.
6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for the rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;285:2370-5.
7. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7.
8. Villani GQ, Piepoli PE, Villani PE, et al. Anticoagulation in atrial fibrillation: what is certain and what is to come. Eur Heart J 2003;24(suppl H):45-50.
9. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(suppl 1):194-206S.
10. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk for stroke: the Framingham study. Stroke 2001;22:983-8.
11. Peterson P, Boysen G, Gofriedsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;i:175-9.
12. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991;84:527-39.
13. European Atrial Fibrillation (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
14. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain haemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997;153:112.
15. European stroke prevention study (ESPS) 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
16. Posada IS, Barriales. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999;138:137-43.
17. Benavate O, Hart R, Koudstaal P, et al. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischaemic attacks. In: Warlow C, Van Gijn J, Sandercock P, eds. Stroke module of the Cochrane Database of Systematic Reviews. Oxford: The Cochrane Collaboration, 1999.
18. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:1492-501.
19. The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
20. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation (SPINAF). N Engl J Med 1992;327:1406-12.
21. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
22. Atrial Fibrillation Investigators. Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
23. Stroke Prevention in Atrial Fibrillation (SPAF) II Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343:687-91.
24. Gulløv AL, Koefoed BG, Petersen TS, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second Copenhagen atrial fibrillation, aspirin, and anticoagulation study. Arch Intern Med 1998;158:1513-21.
25. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of atrial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design. Control Clin Trials 1999;20:386-93.
26. Atrial Fibrillation Investigators. Adjusted-dose warfarin vs low-intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomized clinical trial. Lancet 1996;348:633-8.
27. Fuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary, A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66.
28. Laupicas A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1998;114(suppl 5):579-89S.
29. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischaemia. N Engl J Med 1995;333:5-10.
30. Connolly SJ. Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. Am Heart J 2003;145:418-23.
31. Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med 2003;70:361-71.
32. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8-21S.
33. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
34. Hylek EM, Go AS, Chang Y, et al. Effect of intensify of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26.
35. Hylek EM, Singer DE. Risk factors for intracranial haemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
36. Ibrahim SA, Kwoh CK. Underutilization of oral anticoagulant therapy for stroke prevention in elderly patients with heart failure. Am Heart J 2000;140:219-20.
37. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9.
38. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997;157:441-5.
39. Buckingham TA, Hatala R. Anticoagulants far atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002;25:447-54.
40. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-6.
41. Bungard TJ, Ackman ML, Ho G, et al. Adequacy of anticoagulation in patients with atrial fibrillation coming to a hospital. Pharmacotherapy 2000;20:1060-5.
42. Laupacis A. anticoagulant-related bleeding in older persons with atrial fibrillation: physicians fears often unfounded. Arch Intern Med 2003;163:1580-6.
43. Levine MN, Raskob G, Landefeld S, et al. Haemorrhagic complications of anticoagulant treatment. Chest 2001;119(suppl 1):108-21S.
44. Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995;108(suppl 4):352-9.
45. Sebastian JL, Tresch DD. Use of oral anticoagulants in older patients. Drugs Aging 2000;16:409-35.
46. Hopfner R. Ximelagatran (Astro Zeneca). Curr Opin Investig Drugs 2002;3:246-51.
47. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini review. Thromb Res 2003;109(suppl 1):9-15S.
48. Samama MM, Gerotziafas GT, Elamy I, et al. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 2002;32:218-24.
49. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin 2003;59:35-43.
50. Johansson LC, Frison F, Logrn U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:381-92.
51. Johansson LC, Andersson M, Fager G, et al. No influence of ethnic origin on the pharmacokinetics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003;42:475-84.
52. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-77.
53. Wahlander K, Eriksson-Lepkowska M, Frison L, et al. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:755-64.
54. Eriksson U, Johansson S, Attman PO, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003;42:743-53.
55. Elg M, Carlsson S, Gustafsson D. Effects of agents used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anaesthesized rats and rabbits. Thromb Research 2001;101:159-70.
56. Petersen P, Grind M, Adler J. SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003;41:1445-51.
57. Petersen P. A two year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Neurology 2002;58(suppl 3):A477.
58. Halperin JL. Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-8.
59. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvolvular atrial fibrillation (SPORTIF III): randomised controlled trial. lancet 2003;362:1691-8.
60. Halperin JL. Efficacy and safety study of oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V). Circulation 2003;108:E9051.
61. Wallentin L, Wilcox RG, Weaver WD, et al. ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
62. Schulman S, Wahlander K, Lundstrom T, et al. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-21.
63. Francis CW, Berkowitz SD, Comp PC, et al. EXULT A study group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
64. Eriksson H, Wahlander K, Gustafsson D, et al. THRIVE Investigators. A randomised, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003;1:41-7.
65. Glynn O. The EXPRESS (expanded prophylaxis evaluation surgery study) preliminary results. Int J Clin Pract 2003;57:57-9.
66. Hamaad A, Tayebjee MH, Lip GYH. The METHRO (melagatran for thrombin inhibition in orthopaedic surgery) trials. Expert Opin Investig Drugs 2003;12:865-70.
67. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-55.
68. Sunderji R, Fung A, Gin K, et al. Patient self-management of oral anticoagulation: a review. Can J Cardiol 2003;19:931-5.
69. Koertke H, Minami K, Boethig D, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003;107(suppl 1):II75-8.
70. Coussement PK, Bassand JP, Covens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-24.